Molecular Cancer Therapeutics Chemical and Biological Aspects of Inflammation and Cancer Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Whitehead, C. M.
Right arrow Articles by Thompson, W. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Whitehead, C. M.
Right arrow Articles by Thompson, W. J.
Vol. 2, 479-488, May 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Exisulind-induced Apoptosis in a Non-Small Cell Lung Cancer Orthotopic Lung Tumor Model Augments Docetaxel Treatment and Contributes to Increased Survival

Clark M. Whitehead1, Keith A. Earle, John Fetter, Songmei Xu, Theresa Hartman, Daniel C. Chan, Tom L. M. Zhao, Gary Piazza, Andres J.P. Klein-Szanto, Rifat Pamukcu, Hector Alila, Paul A. Bunn, Jr and W. Joseph Thompson

Cell Pathways, Inc., Horsham, Pennsylvania 19044 [C. M. W., K. A. E., J. F., S. X., T. H., G. P., R. P., H. A., W. J. T.]; University of Colorado Health Sciences Center, Division of Medical Oncology, Denver, Colorado 80262 [D. C. C., T. L. M. Z., P. A. B.]; and Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [A. J. P. K-S.]

1 To whom requests for reprints should be addressed, at Cell Pathways, Inc., 702 Electronic Drive, Horsham, PA 19044. Phone: (215) 706-3800; Fax: (215) 706-3801; E-mail: cwhitehead{at}cellpathways.com

We reported previously a significant increase in survival of nude rats harboring orthotopic A549 human non-small cell lung cancer tumors after treatment with a combination of exisulind (Sulindac Sulfone) and docetaxel (D. C. Chan, Clin. Cancer Res., 8: 904–912, 2002). The purpose of the current study was to determine the biochemical mechanisms responsible for the increased survival by an analysis of the effects of both drugs on A549 orthotopic lung tumors and A549 cells in culture. Orthotopic A549 rat lung tissue sections from drug-treated rats and A549 cell culture responses to exisulind and docetaxel were compared using multiple apoptosis and proliferation analyses [i.e., terminal deoxynucleotidyl transferase-mediated nick end labeling, active caspase 3, the caspase cleavage products cytokeratin 18 and p85 poly(ADP-ribose) polymerase, and Ki-67]. Immunohistochemistry was used to determine cyclic GMP (cGMP) phosphodiesterase (PDE) expression in tumors. The cGMP PDE composition of cultured A549 cells was resolved by DEAE-Trisacryl M chromatography and the pharmacological sensitivity to exisulind, and additional known PDE inhibitors were determined by enzyme activity assays. Exisulind inhibited A549 cell cGMP hydrolysis and induced apoptosis of A549 cells grown in culture. PDE5 and 1 cGMP PDE gene family isoforms identified in cultured cells were highly expressed in orthotopic tumors. The in vivo apoptosis rates within the orthotopic tumors increased 7–8-fold in animals treated with the combination of exisulind and docetaxel. Exisulind increased the in vivo apoptosis rates as a single agent. Docetaxel, but not exisulind, decreased proliferative rates within the tumors. The data indicate that exisulind-induced apoptosis contributed significantly to the increased survival in rats treated with exisulind/docetaxel. The mechanism of exisulind-induced apoptosis involves inhibition of cGMP PDEs, and these results are consistent with a cGMP-regulated apoptosis pathway.




This article has been cited by other articles:


Home page
Cancer Res.Home page
A. Deguchi, W. J. Thompson, and I. B. Weinstein
Activation of Protein Kinase G Is Sufficient to Induce Apoptosis and Inhibit Cell Migration in Colon Cancer Cells
Cancer Res., June 1, 2004; 64(11): 3966 - 3973.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. T. E. Lim, G. A. Piazza, R. Pamukcu, W. J. Thompson, and I. B. Weinstein
Exisulind and Related Compounds Inhibit Expression and Function of the Androgen Receptor in Human Prostate Cancer Cells
Clin. Cancer Res., October 15, 2003; 9(13): 4972 - 4982.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.